JP2011504362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011504362A5 JP2011504362A5 JP2010534367A JP2010534367A JP2011504362A5 JP 2011504362 A5 JP2011504362 A5 JP 2011504362A5 JP 2010534367 A JP2010534367 A JP 2010534367A JP 2010534367 A JP2010534367 A JP 2010534367A JP 2011504362 A5 JP2011504362 A5 JP 2011504362A5
- Authority
- JP
- Japan
- Prior art keywords
- oligomer
- seq
- nucleotide sequence
- lna
- oligomer according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 8
- 102000001307 androgen receptors Human genes 0.000 claims 6
- 108010080146 androgen receptors Proteins 0.000 claims 6
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 108020004999 Messenger RNA Proteins 0.000 claims 3
- 230000000875 corresponding Effects 0.000 claims 3
- 230000003463 hyperproliferative Effects 0.000 claims 3
- 229920002106 messenger RNA Polymers 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-Methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 2
- 230000000295 complement Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 229920000023 polynucleotide Polymers 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99012507P | 2007-11-26 | 2007-11-26 | |
| US60/990,125 | 2007-11-26 | ||
| PCT/DK2008/000417 WO2009068033A2 (en) | 2007-11-26 | 2008-11-26 | Lna antagonists targeting the androgen receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015208689A Division JP2016105703A (ja) | 2007-11-26 | 2015-10-23 | アンドロゲン受容体を標的化するｌｎａアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011504362A JP2011504362A (ja) | 2011-02-10 |
| JP2011504362A5 true JP2011504362A5 (pt) | 2011-12-08 |
| JP5872162B2 JP5872162B2 (ja) | 2016-03-01 |
Family
ID=40379703
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010534367A Expired - Fee Related JP5872162B2 (ja) | 2007-11-26 | 2008-11-26 | アンドロゲン受容体を標的化するｌｎａアンタゴニスト |
| JP2015208689A Pending JP2016105703A (ja) | 2007-11-26 | 2015-10-23 | アンドロゲン受容体を標的化するｌｎａアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015208689A Pending JP2016105703A (ja) | 2007-11-26 | 2015-10-23 | アンドロゲン受容体を標的化するｌｎａアンタゴニスト |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US7737125B2 (pt) |
| EP (1) | EP2225377B1 (pt) |
| JP (2) | JP5872162B2 (pt) |
| KR (1) | KR20100110298A (pt) |
| CN (1) | CN101932709B (pt) |
| AU (1) | AU2008329327B2 (pt) |
| BR (1) | BRPI0820508A2 (pt) |
| CA (1) | CA2705714A1 (pt) |
| DK (1) | DK2225377T3 (pt) |
| EA (1) | EA020026B1 (pt) |
| ES (1) | ES2456990T3 (pt) |
| IL (2) | IL205944A (pt) |
| MX (1) | MX2010005703A (pt) |
| NZ (1) | NZ585327A (pt) |
| TW (1) | TW200930382A (pt) |
| UA (1) | UA100253C2 (pt) |
| WO (1) | WO2009068033A2 (pt) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2475003A1 (en) | 2002-02-01 | 2003-08-07 | Sequitur, Inc. | Double-stranded oligonucleotides |
| WO2003064621A2 (en) | 2002-02-01 | 2003-08-07 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| JP5723154B2 (ja) | 2007-09-19 | 2015-05-27 | アプライド バイオシステムズ リミテッド ライアビリティー カンパニー | ＲＮＡｉにおけるオフターゲット表現型の影響を減少させるためのＳｉＲＮＡ配列非依存性修飾フォーマットおよびその安定化型 |
| US8450290B2 (en) * | 2007-11-26 | 2013-05-28 | Enzon Pharmaceuticals, Inc. | Methods for treating androgen receptor dependent disorders including cancers |
| US8906875B2 (en) | 2010-03-12 | 2014-12-09 | The Brigham And Women's Hospital, Inc. | Methods of treating vascular inflammatory disorders |
| EP2606130B1 (en) * | 2010-08-16 | 2019-03-13 | Duke University | Camkk-beta as a marker in prostate cancer |
| WO2012048113A2 (en) | 2010-10-07 | 2012-04-12 | The General Hospital Corporation | Biomarkers of cancer |
| AU2011326034B2 (en) * | 2010-11-12 | 2016-02-04 | Roche Innovation Center Copenhagen A/S | Compositions and methods for treating androgen receptor dependent disorders including cancers |
| EP3702460A1 (en) | 2010-11-12 | 2020-09-02 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| WO2012097261A2 (en) | 2011-01-14 | 2012-07-19 | The General Hospital Corporation | Methods targeting mir-128 for regulating cholesterol/lipid metabolism |
| EP2717883B1 (en) | 2011-05-02 | 2017-03-22 | Stichting VUmc | Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg) |
| EP3170899B1 (en) | 2011-10-11 | 2020-06-24 | The Brigham and Women's Hospital, Inc. | Microrna mir-155 in neurodegenerative disorders |
| WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
| ES2764381T3 (es) * | 2012-07-27 | 2020-06-03 | Aragon Pharmaceuticals Inc | Métodos y composiciones para determinar la resistencia a la terapia de receptor de andrógenos |
| CA2886116C (en) | 2012-09-26 | 2022-06-07 | Mirrx Therapeutics | Oligomers with improved off-target profile |
| US9175291B2 (en) * | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
| ES2907254T3 (es) * | 2012-10-11 | 2022-04-22 | Ionis Pharmaceuticals Inc | Un compuesto antisentido modificado para su uso en el tratamiento de la enfermedad de Kennedy |
| US20150291958A1 (en) | 2012-11-15 | 2015-10-15 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| KR20150110562A (ko) * | 2013-01-30 | 2015-10-02 | 에프. 호프만-라 로슈 아게 | Ｌｎａ 올리고뉴클레오타이드 탄수화물 컨쥬게이트 |
| EP2774997A1 (en) * | 2013-03-05 | 2014-09-10 | Bayer Pharma Aktiengesellschaft | Detection of Androgen Receptor (AR) mutations in circulating tumor DNA from plasma samples of castration-resistant prostate cancer patients using locked nucleic acid-clamp PCR |
| WO2014171826A1 (en) | 2013-04-17 | 2014-10-23 | Stichting Vu-Vumc | Treatment of cognitive impairment in depressive disorders |
| US9506030B2 (en) | 2013-05-01 | 2016-11-29 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
| AU2014259954B2 (en) | 2013-05-01 | 2019-11-07 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating miR-122 |
| AU2014306416B2 (en) * | 2013-08-16 | 2021-02-25 | Translate Bio Ma, Inc. | Compositions and methods for modulating RNA |
| EP3760208B1 (en) | 2014-06-25 | 2024-05-29 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| US10385343B2 (en) | 2014-08-29 | 2019-08-20 | Children's Medical Center Corporation | Methods and compositions for the treatment of cancer |
| WO2016114655A1 (en) | 2015-01-12 | 2016-07-21 | Ry Pharma B.V. | Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation |
| WO2016130943A1 (en) | 2015-02-13 | 2016-08-18 | Rana Therapeutics, Inc. | Hybrid oligonucleotides and uses thereof |
| EP3283502A4 (en) | 2015-04-07 | 2019-04-03 | The General Hospital Corporation | METHODS FOR REACTIVATION OF GENES ON INACTIVE X CHROMOSOME |
| EP3314250A4 (en) | 2015-06-26 | 2018-12-05 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
| WO2017065602A1 (en) | 2015-10-13 | 2017-04-20 | Ry Pharma B.V. | Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation |
| WO2017066712A2 (en) | 2015-10-16 | 2017-04-20 | The Children's Medical Center Corporation | Modulators of telomere disease |
| WO2017066796A2 (en) | 2015-10-16 | 2017-04-20 | The Children's Medical Center Corporation | Modulators of telomere disease |
| WO2017087708A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
| US11234996B2 (en) | 2016-02-25 | 2022-02-01 | The Brigham And Women's Hospital, Inc. | Treatment methods for fibrosis targeting SMOC2 |
| KR20190003504A (ko) | 2016-03-24 | 2019-01-09 | 유니버시타이트 라이덴 | 식물을 형질주입하고 무작위 통합 사건을 감소시키는 방법 |
| JP6730717B2 (ja) * | 2016-04-14 | 2020-07-29 | 株式会社ｅ−ＮＡ Ｂｉｏｔｅｃ | マイクロｒｎａ−１４３誘導体 |
| RU2753966C2 (ru) * | 2016-08-08 | 2021-08-24 | Олипасс Корпорейшн | Антисмысловые олигонуклеотиды андрогенового рецептора |
| EP3532638A4 (en) | 2016-10-31 | 2020-07-29 | University of Massachusetts | TARGETING MICROARN-101-3 P IN CARCINOTHERAPY |
| US11643655B2 (en) * | 2016-11-15 | 2023-05-09 | City Of Hope | Methods for intracellular delivery and enhanced gene targeting |
| WO2018111099A1 (en) | 2016-12-12 | 2018-06-21 | Stichting Vumc | Biomarkers and treatments for cerebral amyloid angiopathy (caa) |
| WO2018195486A1 (en) | 2017-04-21 | 2018-10-25 | The Broad Institute, Inc. | Targeted delivery to beta cells |
| WO2019036375A1 (en) | 2017-08-14 | 2019-02-21 | Sanford Burnham Prebys Medical Discovery Institute | CARDIOGENIC MESODERMA TRAINING REGULATORS |
| US11413288B2 (en) | 2017-11-01 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancers |
| EP3502259A1 (en) | 2017-12-19 | 2019-06-26 | Universiteit Leiden | A combinational strategy for reducing random integration events when transfecting plants |
| WO2019217369A1 (en) | 2018-05-08 | 2019-11-14 | Regulus Therapeutics Inc. | Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect |
| US20210292766A1 (en) | 2018-08-29 | 2021-09-23 | University Of Massachusetts | Inhibition of Protein Kinases to Treat Friedreich Ataxia |
| WO2020067887A1 (en) | 2018-09-24 | 2020-04-02 | Erasmus University Medical Center Rotterdam | Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses |
| GB201817990D0 (en) * | 2018-11-02 | 2018-12-19 | Univ Of Essex Enterprise Limited | Enzymatic nucleic acid molecules |
| KR102473989B1 (ko) | 2018-11-28 | 2022-12-07 | (주)바이오니아 | 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물 |
| WO2020148400A1 (en) * | 2019-01-16 | 2020-07-23 | Stichting Katholieke Universiteit | Antisense oligonucleotides for use in the treatment of crpc |
| WO2020171889A1 (en) | 2019-02-19 | 2020-08-27 | University Of Rochester | Blocking lipid accumulation or inflammation in thyroid eye disease |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4914210A (en) | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
| US4962029A (en) | 1987-10-02 | 1990-10-09 | Cetus Corporation | Covalent oligonucleotide-horseradish peroxidase conjugate |
| US6733776B1 (en) | 1992-04-02 | 2004-05-11 | Anticancer, Inc. | Method for promoting hair growth |
| AU6554594A (en) | 1993-04-02 | 1994-10-24 | Anticancer, Inc. | Method for delivering beneficial compositions to hair follicles |
| EP0851919A1 (en) | 1995-09-20 | 1998-07-08 | University of Massachusetts Worcester | Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate |
| US6489163B1 (en) | 1996-05-08 | 2002-12-03 | Board Of Regents, The University Of Texas System | Ribozyme mediated inactivation of the androgen receptor |
| KR20020097241A (ko) | 2000-05-04 | 2002-12-31 | 에이브이아이 바이오파마 인코포레이티드 | 스플라이스-영역 안티센스 조성물 및 방법 |
| US20050159376A1 (en) * | 2002-02-20 | 2005-07-21 | Slrna Therapeutics, Inc. | RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA) |
| CA2480311C (en) * | 2002-04-05 | 2015-01-27 | Santaris Pharma A/S | Oligomeric compounds for the modulation of hif-1alpha expression |
| US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| ATE442152T1 (de) | 2002-11-18 | 2009-09-15 | Santaris Pharma As | Antisense-entwurf |
| AU2004204068B8 (en) * | 2003-01-03 | 2010-03-25 | Gencia Corporation | SiRNA Mediated Post - Transcriptional Gene Silencing of Genes involved in Alopecia |
| WO2004069992A2 (en) * | 2003-02-10 | 2004-08-19 | Santaris Pharma A/S | Oligomeric compounds for the modulation of ras expression |
| CA2515554A1 (en) * | 2003-02-10 | 2004-08-19 | Santaris Pharma A/S | Oligomeric compounds for the modulation of thioredoxin expression |
| JP5209204B2 (ja) | 2003-04-13 | 2013-06-12 | エンゾン ファーマスーティカルズ インコーポレイテッド | ポリマーオリゴヌクレオチドプロドラッグ |
| CA2538729A1 (en) * | 2003-09-12 | 2005-03-31 | Avi Biopharma, Inc. | Compound and method for treating androgen-independent prostate cancer |
| US20050164970A1 (en) | 2003-12-22 | 2005-07-28 | University Of Kansas Medical Center | Method for treating prostate cancer using siRNA duplex for androgen receptor |
| DK1706489T3 (da) * | 2003-12-23 | 2010-09-13 | Santaris Pharma As | Oligomer forbindelser for modulationen af BCL-2 |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| EP1931778A2 (en) | 2005-09-15 | 2008-06-18 | Santaris Pharma A/S | RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-Bl00 EXPRESSION |
| US20100286229A1 (en) * | 2005-09-30 | 2010-11-11 | Katerina Gurova | Modulation of Androgen Receptor for Treatment of Prostate Cancer |
| WO2007124751A2 (en) * | 2006-05-01 | 2007-11-08 | Aarhus Universitet | An animal model and a method for producing an animal model |
| ATE513912T1 (de) | 2006-05-05 | 2011-07-15 | Isis Pharmaceuticals Inc | Verbindungen und verfahren zur modulation der expression von sglt2 |
| CA2662520A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
| MX2009002859A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. |
| EP2090127A2 (en) | 2006-10-30 | 2009-08-19 | Nokia Corporation | Method, apparatus and system providing operator controlled mobility for user equipment |
| JP5168944B2 (ja) | 2007-02-28 | 2013-03-27 | 三浦工業株式会社 | 羽根車式流量計 |
-
2008
- 2008-11-26 KR KR1020107012993A patent/KR20100110298A/ko not_active Application Discontinuation
- 2008-11-26 CN CN200880125544.3A patent/CN101932709B/zh not_active Expired - Fee Related
- 2008-11-26 JP JP2010534367A patent/JP5872162B2/ja not_active Expired - Fee Related
- 2008-11-26 DK DK08855697.2T patent/DK2225377T3/da active
- 2008-11-26 EP EP08855697.2A patent/EP2225377B1/en active Active
- 2008-11-26 NZ NZ585327A patent/NZ585327A/xx not_active IP Right Cessation
- 2008-11-26 EA EA201070660A patent/EA020026B1/ru not_active IP Right Cessation
- 2008-11-26 WO PCT/DK2008/000417 patent/WO2009068033A2/en active Application Filing
- 2008-11-26 ES ES08855697.2T patent/ES2456990T3/es active Active
- 2008-11-26 AU AU2008329327A patent/AU2008329327B2/en not_active Ceased
- 2008-11-26 MX MX2010005703A patent/MX2010005703A/es active IP Right Grant
- 2008-11-26 CA CA2705714A patent/CA2705714A1/en not_active Abandoned
- 2008-11-26 UA UAA201007942A patent/UA100253C2/uk unknown
- 2008-11-26 US US12/324,033 patent/US7737125B2/en not_active Expired - Fee Related
- 2008-11-26 TW TW097145706A patent/TW200930382A/zh unknown
- 2008-11-26 BR BRPI0820508A patent/BRPI0820508A2/pt not_active IP Right Cessation
-
2010
- 2010-03-18 US US12/726,554 patent/US7989429B2/en not_active Expired - Fee Related
- 2010-05-25 IL IL205944A patent/IL205944A/en not_active IP Right Cessation
-
2011
- 2011-05-31 US US13/149,155 patent/US20110319471A1/en not_active Abandoned
-
2012
- 2012-10-11 IL IL222397A patent/IL222397A/en not_active IP Right Cessation
-
2015
- 2015-10-23 JP JP2015208689A patent/JP2016105703A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011504362A5 (pt) | ||
| JP2018184423A5 (pt) | ||
| RU2501803C2 (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| JP6622214B2 (ja) | Ｓｏｄ−１発現を調節するための組成物 | |
| RU2566724C2 (ru) | Композиции и способы модуляции smn2 сплайсинга у субъекта | |
| JP2010524486A5 (pt) | ||
| AU2012358238B2 (en) | Methods for modulating Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1(MALAT-1) expression | |
| JP2011526482A5 (pt) | ||
| JP2012050438A5 (pt) | ||
| JP2009532044A5 (pt) | ||
| JP2016530882A5 (pt) | ||
| JP2009508527A5 (pt) | ||
| JP2009532392A5 (pt) | ||
| PT1910395E (pt) | Composições e métodos para a modulação do''splicing'' de smn2 | |
| BR112018005223B1 (pt) | Compostos, uso dos mesmos, e composição farmacêutica | |
| JP2005503142A5 (pt) | ||
| JP2009515523A (ja) | Ｔｎｆスーパーファミリー受容体に対するスプライス切替オリゴマーならびに疾病治療における該オリゴマーの使用 | |
| JP2010539950A5 (pt) | ||
| JP2021527437A (ja) | Ｓｃｎ９ａ発現を調節するためのオリゴヌクレオチド | |
| JP2015511821A5 (pt) | ||
| BR112020020220A2 (pt) | Uso de inibidores da fubp1 para o tratamento de infecção pelo vírus da hepatite b | |
| WO2019215175A1 (en) | Oligonucleotides for modulating myh7 expression | |
| WO2019233922A1 (en) | Oligonucleotides for modulating atxn2 expression | |
| TW202307207A (zh) | 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| BR122020018622A2 (pt) | Molécula de ácido nucleico para redução de papd5 e papd7 de mrna para o tratamento de infecção hepatite b |